IRCT20200816048422N1已完成1 期
Efficacy of Daclatasvir+Sofosbuvir in patients with severe acute respiratory syndrome coronavirus (SARS-COVID-19)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Age over 18 years old
- •Respiratory rate more than 30 per minute Oxygen saturation less than 93%
- •Confirmation of pneumonia by diagnostic CT scan of the chest
排除标准
- •Taking the drug Amiodarone
- •Kidney failure
研究者
相似试验
已完成
3 期
Hepatitis C Treatment in a Community-based SettingIRCT20170213032547N1Kerman University of Medical Sciences110
已完成
3 期
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCVIRCT20080901001155N30Rasht University of Medical Sciences16
已完成
3 期
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19IRCT20200624047908N1Abadan University of Medical Sciences1,000
招募中
2 期
Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled studyCOVID-19SARS-nCoV-2 infectionDRKS00022203PHARCO CORPORATE90
已完成
2 期
Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19COVID-19.2019-nCOV diseaseU07.1IRCT20200324046850N2Abadan University of Medical Sciences62